Monopar Therapeutics stock price prediction: Short-term downside risk with $63.8 support in focus
Monopar Therapeutics (MNPR) stock is trading at $70.66, marking a daily decline of 4.19%. The price currently sits below its key short-term averages but still retains some support from longer-term levels.
73.9900
75.2600
Highlights
- MNPR/USD trades below both short- and long-term moving averages with price at $70.66, down 4.19% on the day.
- Momentum indicators are mixed, with positive intraday buyer power contrasted by neutral readings from oscillators and the AO.
- Expected range over the next few days is $63.802 to $77.518, with 57% probability of an upward move and $71.10 as key resistance.
Mixed momentum as resistance caps price and buyers dominate intraday
On the hourly chart, MNPR is trading below the MA-20 but remains above the MA-50, while the daily chart shows the price is under the MA-200. The Ichimoku Kijun level at $71.10 acts as immediate resistance. Momentum indicators are mixed: MACD and ADX show ongoing buying interest, yet RSI, Stochastic RSI, and CCI all sit in neutral territory. Bull/Bear Power remains positive at 2.4873, indicating buyers' dominance intraday, while the Awesome Oscillator is neutral.
Upward bias likely amid rangebound risks and volatile support tests
In the short term, the expected trading range for MNPR is between $63.80 and $77.51, with a 57% probability favoring an upward move and a 43% risk of further declines. Should the price stabilize, it may remain in a sideways channel, but a decisive break above $71.10 resistance could trigger a higher move. Conversely, a failure to hold key support levels may open the way for additional downside within the current volatility band.
Earlier, analysts noted that Monopar Therapeutics was in a period of technical consolidation, with a potential shift toward a bullish breakout under observation. The current setup adds nuance by showing intraday buyer dominance against a backdrop of mixed momentum signals, highlighting $71.10 as a pivotal resistance level for traders to watch in the near term.
Latest Monopar Therapeutics News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
